Envista Holdings Corporation Stock
Stocks
NVST
US29415F1049
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
16:00:03 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 23.51 USD | -4.47% |
|
-0.38% | +8.29% |
| 10-15 | Baird Downgrades Envista Holdings to Neutral From Outperform, Price Target is $26 | MT |
| 09-18 | Envista Stock Volatility Reflects Expectations, Not Negative News, UBS Says | MT |
| Market Cap | 3.78B 3.38B 3.11B 2.82B 5.27B 359B 5.37B 37.1B 14.89B 189B 14.17B 13.87B 595B | P/E 2026 * |
21.5x | P/E 2027 * | 20.4x |
|---|---|---|---|---|---|
| Enterprise Value | 3.81B 3.42B 3.14B 2.85B 5.32B 362B 5.42B 37.47B 15.04B 191B 14.31B 14.01B 601B | EV / Sales 2026 * |
1.33x | EV / Sales 2027 * | 1.2x |
| Free-Float |
90.51% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| NVST | Delayed | |
CBOE
| NVST | Real-time | |
|
Boerse Muenchen
| 0HV | Real-time | |
|
Deutsche Boerse AG
| 0HV | Delayed | |
|
Börse Stuttgart
| 0HV | Delayed | |
|
Tradegate
| 0HV | Real-time |
Last Transcript: Envista Holdings Corporation
| 1 day | -4.47% | ||
| 1 week | -0.38% | ||
| 1 month | +0.17% | ||
| 3 months | -13.91% | ||
| 6 months | -9.37% | ||
| Current year | +8.29% |
| 1 week | 23.4 |  | 24.9 |
| 1 month | 22.2 | | 24.9 |
| Current year | 21.58 | | 30.42 |
| 1 year | 18.77 | | 30.42 |
| 3 years | 14.22 | | 30.42 |
| 5 years | 14.22 | | 52.03 |
| 10 years | 10.08 | | 52.03 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Keel
CEO | Chief Executive Officer | 56 | 2024-04-30 |
Eric Hammes
DFI | Director of Finance/CFO | 51 | 2024-08-07 |
Paul Sumilas
CMP | Compliance Officer | - | 2023-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Raskas
BRD | Director/Board Member | 59 | 2018-12-31 |
Wendy Carruthers
BRD | Director/Board Member | 57 | 2018-12-31 |
R. Huennekens
CHM | Chairman | 61 | 2018-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/25/26 | Tax | President, Nobel Biocare | -804 | 0.0005% | - | |
| 8/25/26 | Tax | Chief Financial Officer | -10,885 | 0.0067% | ||
| 8/25/26 | Tax | President, Orthodontics | -7,710 | 0.0047% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.47% | -0.38% | +15.53% | +1.03% | 3.78B | |
| +1.56% | +2.41% | -14.09% | +12.32% | 184B | |
| -0.59% | +1.18% | +6.44% | +36.82% | 118B | |
| -6.38% | -4.98% | -18.07% | +8.01% | 111B | |
| +3.42% | +1.71% | -41.92% | +8.01% | 94.58B | |
| +0.09% | -0.05% | -2.06% | +78.69% | 63.13B | |
| -0.46% | +0.42% | +4.48% | +82.84% | 55.66B | |
| -0.23% | -0.52% | +10.73% | -21.72% | 53.9B | |
| -4.30% | -1.64% | -12.44% | +37.99% | 43.42B | |
| +0.58% | +2.00% | -1.17% | -8.82% | 34.68B | |
| Average | -1.08% | +0.01% | -5.26% | +23.52% | 76.22B | |
| Weighted average by Cap. | -0.50% | +0.24% | -10.00% | +23.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.88B 2.58B 2.37B 2.15B 4.01B 273B 4.09B 28.26B 11.35B 144B 10.8B 10.57B 453B | 2.98B 2.67B 2.46B 2.23B 4.16B 283B 4.24B 29.29B 11.76B 149B 11.19B 10.95B 470B |
| Net income | 168M 151M 139M 126M 235M 15.97B 239M 1.65B 663M 8.4B 631M 618M 26.49B | 170M 153M 140M 127M 238M 16.18B 242M 1.67B 672M 8.51B 640M 626M 26.84B |
| Net Debt | 38.01M 34.04M 31.31M 28.37M 53.03M 3.61B 54.03M 373M 150M 1.9B 143M 140M 5.99B | -188M -168M -155M -140M -262M -17.81B -267M -1.84B -740M -9.37B -704M -689M -29.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-30 | US$23.51 | -4.47% | 3,727,983 |
| 26-10-29 | US$24.61 | +2.80% | 2,924,719 |
| 26-10-28 | US$23.94 | +1.53% | 3,188,396 |
| 26-10-27 | US$23.58 | -0.34% | 2,059,163 |
| 26-10-26 | US$23.66 | +0.25% | 3,153,610 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NVST Stock
Select your edition
All financial news and data tailored to specific country editions
